153 related articles for article (PubMed ID: 9489486)
1. Antitumor effect of L-deprenyl in rats with carcinogen-induced mammary tumors.
ThyagaRajan S; Felten SY; Felten DL
Cancer Lett; 1998 Jan; 123(2):177-83. PubMed ID: 9489486
[TBL] [Abstract][Full Text] [Related]
2. L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.
ThyagaRajan S; Quadri SK
Endocrine; 1999 Jun; 10(3):225-32. PubMed ID: 10484286
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effect of L-deprenyl is associated with enhanced central and peripheral neurotransmission and immune reactivity in rats with carcinogen-induced mammary tumors.
ThyagaRajan S; Madden KS; Stevens SY; Felten DL
J Neuroimmunol; 2000 Sep; 109(2):95-104. PubMed ID: 10996211
[TBL] [Abstract][Full Text] [Related]
4. L-Deprenyl stimulates the release of catecholamines in the rat medial basal hypothalamus in vivo.
ThyagaRajan S; Quadri SK
Neurosci Lett; 1999 Jul; 270(2):79-82. PubMed ID: 10462102
[TBL] [Abstract][Full Text] [Related]
5. Deprenyl reinitiates estrous cycles, reduces serum prolactin, and decreases the incidence of mammary and pituitary tumors in old acyclic rats.
Thyagarajan S; Meites J; Quadri SK
Endocrinology; 1995 Mar; 136(3):1103-10. PubMed ID: 7867565
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor growth by L-deprenyl involves neural-immune interactions in rats with spontaneously developing mammary tumors.
Thyagarajan S; Madden KS; Stevens SY; Felten DL
Anticancer Res; 1999; 19(6B):5023-8. PubMed ID: 10697505
[TBL] [Abstract][Full Text] [Related]
7. Region-specific alterations in the concentrations of catecholamines and indoleamines in the brains of young and old F344 rats after L-deprenyl treatment.
ThyagaRajan S; Stevens SY; Felten DL
Brain Res Bull; 1999 Mar; 48(5):513-20. PubMed ID: 10372512
[TBL] [Abstract][Full Text] [Related]
8. Prevention of Mammary Tumor Development through Neuroimmunomodulation in the Spleen and Lymph Nodes of Old Female Sprague-Dawley Rats by L-Deprenyl.
ThyagaRajan S; Tran L; Molinaro CA; Gridley DS; Felten DL; Bellinger DL
Neuroimmunomodulation; 2013; 20(3):141-51. PubMed ID: 23445569
[TBL] [Abstract][Full Text] [Related]
9. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
10. Deprenyl stimulates the efflux of monoamines from the rat hypothalamus in vitro.
MohanKumar PS; MohanKumar SM; Quadri SK
Brain Res Bull; 2001 Apr; 54(6):675-80. PubMed ID: 11403995
[TBL] [Abstract][Full Text] [Related]
11. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
12. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
13. (-)-Deprenyl treatment restores serum insulin-like growth factor-I (IGF-I) levels in aged rats to young rat level.
De la Cruz CP; Revilla E; Rodríguez-Gómez JA; Vizuete ML; Cano J; Machado A
Eur J Pharmacol; 1997 May; 327(2-3):215-20. PubMed ID: 9200562
[TBL] [Abstract][Full Text] [Related]
14. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
Bondiolotti GP; Galva MD; Villa F; Sciaba L; Picotti GB
Biochem Pharmacol; 1995 Jun; 50(1):97-102. PubMed ID: 7605351
[TBL] [Abstract][Full Text] [Related]
15. Restoration of sympathetic noradrenergic nerve fibers in the spleen by low doses of L-deprenyl treatment in young sympathectomized and old Fischer 344 rats.
ThyagaRajan S; Felten SY; Felten DL
J Neuroimmunol; 1998 Jan; 81(1-2):144-57. PubMed ID: 9521616
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: An autoradiographic study.
Nishi K; Mück-Seler D; Hasegawa S; Watanabe A; Diksic M
Brain Res Bull; 2006 Oct; 70(4-6):368-77. PubMed ID: 17027772
[TBL] [Abstract][Full Text] [Related]
17. L-Deprenyl reverses age-associated decline in splenic norepinephrine, interleukin-2 and interferon-γ production in old female F344 rats.
Thyagarajan S; Madden KS; Boehm GW; Stevens SY; Felten DL; Bellinger DL
Neuroimmunomodulation; 2013; 20(2):72-8. PubMed ID: 23207416
[TBL] [Abstract][Full Text] [Related]
18. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of chorionic gonadotropin on DMBA-induced mammary carcinogenesis.
Russo IH; Koszalka M; Gimotty PA; Russo J
Br J Cancer; 1990 Aug; 62(2):243-7. PubMed ID: 2117463
[TBL] [Abstract][Full Text] [Related]
20. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
